Hormonal IUD (Mirena/Kyleena) Monitoring Schedule: Labs and Exams You Actually Need

How the Hormonal IUD Works: Mechanism You Should Understand Before Your Appointment

The levonorgestrel IUD releases a small, continuous dose of progestin directly into the uterine cavity. Mirena (52 mg) releases approximately 20 mcg of levonorgestrel per day at insertion, declining to roughly 10 mcg per day after 5 years. Kyleena (19.5 mg) releases about 9 mcg per day, which is why its hormonal footprint feels lighter to many users.

Local vs. Systemic Action

The primary contraceptive effect is local: the LNG thickens cervical mucus to block sperm penetration, suppresses endometrial proliferation, and, at higher doses (Mirena), partially inhibits ovulation in approximately 45 to 75% of cycles in the first year, with ovulation rates rising again by year 3 to 4 as the daily dose declines. This matters clinically because most women continue ovulating, which means their estrogen levels and cycle-related symptoms persist even when periods stop.

Kyleena suppresses ovulation less consistently. This is why some women notice more cyclic mood changes or breast tenderness on Kyleena compared to Mirena, even though both devices deliver only progestin.

Why Systemic Absorption Still Matters

Serum LNG levels are measurable and real. Peak serum concentrations after Mirena insertion run approximately 150 to 200 pg/mL, which is far below oral LNG contraceptive levels but not zero. Women with lower body weight may experience proportionally higher serum concentrations. This systemic absorption is the reason hormonal side effects, including acne, mood changes, and libido shifts, can occur even with an intrauterine device.

The Monitoring Schedule: What Happens When

Most monitoring after a hormonal IUD is symptom-driven, not protocol-driven. The exception is the mandatory 4-to-6-week post-insertion visit.

The 4-to-6-Week String Check

This visit has one primary purpose: confirm the IUD is still in place and positioned correctly. Your clinician will visualize the strings at the cervical os. If strings are not visible, a pelvic ultrasound is the next step, not immediate removal.

ACOG Practice Bulletin 186 recommends this visit for all IUD insertions. At this appointment your clinician should also review:

• Bleeding pattern since insertion (spotting and irregular bleeding for 3 to 6 months is normal)
• Cramping or pelvic pain (persistent or severe pain warrants evaluation for expulsion or malposition)
• Signs of infection (fever, purulent discharge, uterine tenderness)

Routine STI screening at this visit is appropriate only if you have new risk factors since your pre-insertion screen. It is not automatically required.

Annual Well-Woman Visits

After the 4-to-6-week check, you return to your standard annual well-woman schedule. The IUD itself does not require dedicated annual monitoring separate from your routine preventive care. ACOG's well-woman care guidelines recommend that these annual visits include:

• Blood pressure measurement
• Cervical cancer screening per age and history (Pap smear every 3 years ages 21 to 65, or co-test with HPV every 5 years ages 30 to 65)
• STI screening based on risk
• Discussion of any bleeding changes, mood symptoms, or pelvic pain

The IUD does not change your cervical cancer screening interval. Pap smears can be performed with an IUD in place without removing the device.

When to Come In Outside the Annual Schedule

You should contact your clinician, not wait for your annual visit, if you experience:

• Persistent pelvic pain or cramping beyond 3 months post-insertion
• Fever or chills suggesting pelvic inflammatory disease
• You cannot feel your strings after being able to feel them previously
• A positive home pregnancy test
• Significant mood changes, depression, or worsening anxiety that began after insertion
• New or worsening acne that started after insertion
• Unexplained weight gain or bloating persisting beyond 3 months

Labs and Tests: What Is Actually Indicated and When

There is no standard blood panel required for LNG-IUD monitoring. This is worth stating plainly because many women arrive expecting lab work that is not indicated. Labs are ordered when specific symptoms or clinical scenarios arise.

Pregnancy Test

A urine or serum hCG is ordered if:

• You have missed your period and previously had regular cycles on the IUD
• You develop lower abdominal pain asymmetrically (rule out ectopic)
• You feel nauseous in a pattern that concerns you

The first-year failure rate of Mirena is approximately 0.1 to 0.2%, making pregnancy uncommon but not impossible. When pregnancy does occur with any IUD in place, the risk of ectopic implantation is disproportionately elevated: roughly 50% of pregnancies that occur with an IUD are ectopic. This is a medical emergency. A positive pregnancy test with an IUD in place requires same-day evaluation.

Hemoglobin and Iron Studies

If you had the IUD placed specifically for heavy menstrual bleeding, a baseline hemoglobin and ferritin are reasonable before insertion and again at 6 months. The NEJM 2013 ECLIPSE trial demonstrated that the LNG-IUS (Mirena 52 mg) reduced menstrual blood loss by a median of 71% at 1 year compared with a 24% reduction in the usual-care group, with significantly greater improvement in quality of life. Women using Mirena for HMB should expect measurable hemoglobin improvement within 3 to 6 months if the device is working.

If your bleeding has not meaningfully improved by 6 months, labs plus a pelvic ultrasound to rule out fibroids, polyps, or malposition are warranted.

Hormone Panel

Routine FSH, LH, estradiol, or progesterone testing is not indicated for LNG-IUD monitoring in women of reproductive age. The device is not designed to suppress the HPG axis consistently and most women continue cycling.

The exception is the perimenopausal woman (see Life Stage section below), where FSH testing may be used to gauge ovarian reserve and guide decisions about when the device can be relied upon as the sole contraceptive.

Thyroid Function

The LNG-IUD does not directly affect thyroid function. Thyroid testing is warranted if you develop symptoms: fatigue, hair loss, weight changes, or mood disturbance that is new or worsening. These symptoms overlap with potential LNG side effects, so TSH is a reasonable first test to exclude hypothyroidism as a concurrent cause.

Liver Function Tests

Oral progestins can affect liver enzymes in rare cases. The systemic LNG exposure from an IUD is much lower than oral doses, and routine liver function monitoring is not indicated unless you have pre-existing liver disease or are taking medications that require hepatic monitoring.

Life Stage Differences: How the Monitoring Changes Across Your Reproductive Years

Reproductive Years (Ages 18 to 40, No Fertility Plans Immediately)

Monitoring is at its simplest here. String check at 4 to 6 weeks, then annual well-woman care. The main clinical watchpoints are:

• Irregular bleeding in months 1 to 6 (expected, not alarming)
• Amenorrhea after month 6 (common with Mirena, less common with Kyleena; reassure after ruling out pregnancy)
• Acne or mood changes (may improve with time; consider dermatologic co-management if persistent)

Trying to Conceive (Preparing for Removal)

There is no mandatory washout period after LNG-IUD removal. Fertility returns rapidly: ovulation has been documented as early as the first cycle after removal. No fertility workup is needed solely because of IUD use. If you have been trying for 12 months without success after removal (6 months if you are over 35), proceed with standard fertility evaluation as you would for any woman.

Postpartum and Lactation

Immediate postpartum IUD insertion (within 10 minutes of placental delivery) is safe and supported by ACOG Practice Bulletin 186. Expulsion rates are higher with immediate postpartum insertion, around 10 to 27%, compared to interval insertion. The 4-to-6-week string check is especially important in this group.

Regarding lactation: the LNG-IUD is considered compatible with breastfeeding by the CDC Medical Eligibility Criteria. The amount of LNG transferred to breast milk is low. Infant serum LNG levels in studies have been below detection thresholds or at negligible concentrations. A 2010 systematic review found no effect on milk volume or infant growth at standard progestin-only doses. The CDC assigns it a Category 2 (advantages generally outweigh risks) for the first 6 weeks postpartum and Category 1 (no restriction) after that.

Perimenopause

This is where the monitoring picture becomes meaningfully more complex. In perimenopause (typically ages 45 to 55, though onset varies), the LNG-IUD serves up to three simultaneous roles:

1. Contraception (pregnancy remains possible until 12 months of amenorrhea post-menopause)
2. Management of the erratic, often heavy bleeding that characterizes perimenopause
3. Endometrial protection (progestogen component) for women using systemic estrogen therapy

For women using the LNG-IUD alongside systemic estrogen for menopausal symptoms, The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement supports the 52-mg LNG-IUS as an effective progestogen for endometrial protection, noting that endometrial hyperplasia rates are <1% in women using this combination.

Monitoring additions for perimenopausal women include:

• FSH testing if you need to determine whether you have reached menopause (FSH >40 IU/L on two occasions 6 weeks apart is consistent with menopause, but the IUD makes cycle-based dating unreliable)
• Endometrial biopsy if unexpected bleeding occurs or if you have risk factors for endometrial cancer (obesity, diabetes, prolonged anovulation, tamoxifen use)
• Bone density (DEXA) per standard perimenopausal guidelines, not because of the IUD itself but because this life stage warrants baseline assessment

The LNG-IUD does not replace systemic estrogen for vasomotor symptoms. If you are using the IUD for endometrial protection only, you still need adequate estrogen for bone, cardiovascular, and symptom management.

Post-Menopause

The LNG-IUD is not typically used as a standalone device in post-menopausal women. If one was placed in perimenopause and menopause has been confirmed (12 months of amenorrhea), the device can remain in place if it is within its approved duration and you are using it for endometrial protection alongside estrogen therapy. Monitoring in this group mirrors perimenopausal care: annual visits, endometrial biopsy for any unscheduled bleeding, and standard bone health assessment.

Conditions the LNG-IUD Touches: PCOS, Endometriosis, Fibroids, and More

PCOS

Women with PCOS have a substantially elevated risk of endometrial hyperplasia due to chronic anovulation and unopposed estrogen. ACOG Practice Bulletin 194 on PCOS recommends progestin-based endometrial protection. The LNG-IUD is one effective option. Monitoring in women with PCOS on an LNG-IUD should include:

• Annual discussion of endometrial health
• Low threshold for endometrial biopsy if breakthrough bleeding is heavy or irregular (beyond the expected early-insertion spotting)
• Metabolic monitoring (fasting glucose, lipids) is warranted for PCOS itself, not because of the IUD, since systemic LNG levels from the device are not associated with clinically significant glucose or lipid changes at IUD doses

Endometriosis

The LNG-IUD reduces pain and lesion activity in women with endometriosis. A Cochrane review (2014) found the LNG-IUS effective for reducing dysmenorrhea and endometriosis-associated pain scores. Monitoring should include a symptom review at each visit, with imaging or specialist referral if pain returns or changes character.

Uterine Fibroids

Fibroids do not automatically preclude IUD use, but cavity-distorting fibroids are a relative contraindication. Women with fibroids and an LNG-IUD should have a pelvic ultrasound if:

• Bleeding worsens significantly after an initial period of improvement
• New pelvic pressure or pain develops
• Strings become non-palpable (a fibroid may shift device position)

Female Pattern Hair Loss and Androgenic Acne

Levonorgestrel has moderate androgenic activity compared with other progestins. Women with androgenic alopecia or acne-prone skin may notice worsening, particularly with Mirena (higher LNG dose). Kyleena's lower systemic exposure makes it a preferable first choice in women who have experienced androgen-related side effects on oral LNG-containing pills. This is not a monitoring protocol item per se, but it is a clinical selection factor that is too often overlooked at the prescribing stage.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

The LNG-IUD is contraindicated in confirmed intrauterine pregnancy. This is stated plainly on the Mirena prescribing information. If pregnancy is diagnosed and the device is in place, removal is recommended because leaving it in place increases the risk of septic abortion, preterm birth, and pregnancy loss. Removal itself also carries a risk of pregnancy loss, estimated at approximately 20%, so the decision requires careful shared counseling.

There is no FDA pregnancy category under the current labeling system (replaced in 2015 by the Pregnancy and Lactation Labeling Rule, PLLR). Under PLLR, the Mirena label states: animal studies showed fetal harm at doses far exceeding human exposure; human data are inadequate to fully characterize fetal risk from in-utero LNG exposure at device concentrations.

Lactation: The LNG-IUD is compatible with breastfeeding, as described in the Life Stage section above. The CDC Medical Eligibility Criteria rates it as Category 1 (no restriction) after 6 weeks postpartum.

Contraception requirements: The IUD itself is the contraception. No additional hormonal contraceptive is needed. Use barrier methods for the first 7 days after insertion if you were not on another hormonal method immediately before insertion or if you are not in the first 7 days of your menstrual cycle at insertion.

Return to fertility: Fertility returns within days to weeks of removal. If you plan to conceive within 3 months of IUD removal, folic acid supplementation (400 mcg daily for most women, 4 mg daily if you have a prior neural tube defect pregnancy) should start before removal.

Who This Is Right for and Who Should Think Twice

Good Candidates Across Life Stages

• Women aged 18 to 45 wanting highly effective, low-maintenance contraception (>99% effective per year)
• Women with heavy menstrual bleeding (Mirena 52 mg specifically; not Kyleena)
• Women with PCOS needing endometrial protection who cannot tolerate or prefer not to take oral progestins
• Perimenopausal women who want contraception plus the progestogen component of menopausal hormone therapy in one device
• Women with endometriosis-associated pain on hormonal therapy
• Breastfeeding women who want highly effective non-estrogen contraception

Women Who Should Have a Detailed Conversation First

• Women with cavity-distorting fibroids or uterine anomalies (insertion may not be possible or effective)
• Women with active pelvic inflammatory disease or a history of PID within the past 3 months
• Women with known or suspected uterine or cervical malignancy
• Women with unexplained uterine bleeding before evaluation
• Women with severe androgenic alopecia or acne who are sensitive to androgenic progestins
• Women with Wilson's disease (copper IUD contraindicated; LNG-IUD is an alternative, but discuss)
• Women with liver disease (systemic LNG metabolism may be altered, though IUD doses are low)

What Your Monitoring Visit Should Actually Look Like: A Practical Checklist

Too many women leave their IUD follow-up visits unsure whether anything was actually checked. Here is what a thorough 4-to-6-week visit and annual visit should cover.

4-to-6-Week Post-Insertion Visit:

• Speculum exam to visualize strings
• Bimanual exam if you report pain
• Urine pregnancy test if period has not occurred and you are concerned
• STI screen if new risk factors since pre-insertion screen
• Symptom review: bleeding, pain, mood, acne, headache
• Confirm you know how to check your own strings at home

Annual Well-Woman Visit with IUD in Place:

• Blood pressure, weight, BMI discussion
• Pelvic exam and cervical cancer screening per guidelines
• STI screening per risk
• Discussion of bleeding pattern changes
• Assess mood, libido, and any androgenic symptoms
• Review IUD expiration date and discuss replacement planning
• If perimenopausal: discuss FSH, bone health, and whether estrogen is being considered alongside the device